ArticleBreast cancer research and treatment2012

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Anneleen Daemen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.